急性ST段抬高性心肌梗死的溶栓治疗_毕业论文网 抗体技术对第二代产品进行改造而制成的新的产品,主要特点是半衰期延长,适合静脉给药。这类药包括t-PA的变异体如瑞替普酶(reteplase,r-PA)、兰托普酶(lanetoplase,n-PA)、TNK-组织型纤溶酶原激活剂(TNK-tPA),吸血
基于4个网页-相关网页
Reteplase for InJection 注射用瑞替普酶
Recombinant Reteplase 重组人组织型纤溶酶原激酶衍生物
hirudin and reteplase fusion protein 水蛭素12肽与瑞替普酶融合蛋白
The recanalization rate at 2 hours after thrombolysis was 86.7% in GBV-PA high-dose group, 88.9% in reteplase group, 57.9% in urokinase group and 0.00% in control group. There was significant difference in each thrombolytics groups compared with the control group.
溶栓后2小时GBV-PA大剂量组、瑞替普酶组、尿激酶组、生理盐水组的血管再通率分别为86.7%、88.9%、57.9%和0.00%,各溶栓剂组与生理盐水对照组比较均有统计学差异。
参考来源 - 短尾蝮蛇毒纤溶酶原激活剂颈内动脉溶栓的实验研究·2,447,543篇论文数据,部分数据来源于NoteExpress
应用推荐